Reported Saturday, Johnson & Johnson's Phase 2 DAHLIAS Study Reveals Nipocalimab Yields Over 70% Improvement in Sjögren's Disease Activity Compared To Placebo
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's Phase 2 DAHLIAS study reveals that nipocalimab yields over 70% improvement in Sjögren's disease activity compared to placebo. This is significant as Sjögren's disease currently has no approved advanced treatments.
June 17, 2024 | 7:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's Phase 2 DAHLIAS study shows that nipocalimab yields over 70% improvement in Sjögren's disease activity compared to placebo. This is a significant breakthrough for a disease with no approved advanced treatments.
The positive results from the Phase 2 DAHLIAS study for nipocalimab in treating Sjögren's disease, a condition with no approved advanced treatments, could lead to increased investor confidence and a potential rise in JNJ's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100